Antibodies

#Antibodies #Biotechnology

Exclusive: The man behind the next generation antibody discovery platform

Last year IONTAS, a biotechnology company focused on antibody discovery and development, entered into a licensing agreement with Bristol Myers Squibb for its proprietary mammalian display. John McCafferty, nuclease directed mammalian display inventor and co-inventor of antibody phage display, told Lu Rahman about this breakthrough work. The company operates as… Read More

#Exclusive Content #News #Opinion

#Antibodies #Drug discovery

Flow Eighteen38, a new protein sciences service

FairJourney Biologics (FJB) and IONTAS, specialists in the discovery and optimisation of antibodies, have launched of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterisation data on antibody panels and leads. As… Read More

#News

#Antibodies

A rapid method to quantitatively screen bispecific antibody using protein A and His1K biosensors

Recent biotechnological advances have fueled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the wide array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for… Read More

#Resources

#Antibodies #Assay development & optimisation #Bispecific therapeutics

Fast way to screen bispecific antibodies using protein A and His1K biosensors

Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs… Read More

#News

#Antibodies #Covid-19 #Drug discovery

How to achieve accurate affinity profiling of a SARS-CoV-2 antibody in serum

Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Fluidic Analytics’ application note explains why current technologies provide only an incomplete understanding of the… Read More

#Covid-19 #News

#Antibodies

OXGENE’s SLIM platform for discovery of antibodies against membrane proteins

OXGENE has announced the introduction of its self-labelling integral membrane (SLIM) protein discovery system. The novel method allows for the identification of antibodies against membrane proteins in their native configuration in mammalian cells, which could catalyse the discovery of new candidates for antibody-based therapies. In SLIM display, a target membrane… Read More

#News

#AI / data analytics / healthtech / informatics #Antibodies #Biotechnology #Cancer research #Drug development #Oncology

AI-driven precision medicine for development of HMBD-001 in HER3-driven cancers

Hummingbird Bioscience, a clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, is collaborating with Tempus, an expert in artificial intelligence and precision medicine. This will drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbour… Read More

#Cancer Research #News

#Antibodies #Covid-19 #Novel therapeutics

Fusion Antibodies and Queen’s University get grant to develop COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts. Within the framework of their Northern Ireland Coronavirus Antibody Development Alliance (NICADA), the two organisations will use… Read More

#Covid-19 #Editor's Choice #News

#Antibodies #Therapeutics

Evotec and Sartorius partner with start-up focussed on therapeutic exosomes

Evotec and Sartorius have teamed up with recently established Curexsys, a German technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables the company to… Read More

#News

#Antibodies #Biotechnology

Sterling announces strategic investment in ADC Biotechnology

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions (Sterling), has announced a new strategic partnership with ADC Biotechnology (ADC Bio), a UK based biotechnology company specialising in antibody drug conjugates. The partnership will see Sterling make a significant investment in the business with a view to acquiring ADC… Read More

#News

#Antibodies #Therapeutics

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics and IONTAS have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases. Pandion focuses on the development of innovative modular therapeutics using its… Read More

#News

#Antibodies #Covid-19

Method finds COVID-19 monoclonal antibody among a trillion possibilities

University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralising human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method– as well as a trio of successful animal studies on an antibody called ‘Ab1’– are described today in the Proceedings of the… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Novel candidates #Therapeutics

Novel COVID-19 antibody therapy candidates identified by UK biotech consortium

The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody ‘cocktail’. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibodies #Biologics / Biotechnology #Therapeutics

Just-Evotec Biologics gets grant for antibody product for the prevention of COVID-19

Evotec’s Seattle-based subsidiary, Just–Evotec Biologics has received a grant from the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (mAb) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Under… Read More

#Covid-19 #News